X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
GLB-COV2-043 is a promising booster vaccine candidate component for adult participants who have received the 2-dose priming course of the mRNA BNT162b2 vaccine against COVID-19.
Lead Product(s): GLB-COV2-043
Therapeutic Area: Infections and Infectious Diseases Product Name: GLB-COV2-043
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2023
Details:
Under the collaboration, GreenLight Biosciences and Epivax Therapeutics will design and develop new personalized mRNA-based cancer vaccine candidates using GreenLight and EpiVax Therapeutics technology platforms.
Lead Product(s): mRNA-based Vaccine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Vaccine
Partner/Sponsor/Collaborator: EpiVax
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 09, 2023
Details:
GreenLight—in collaboration with the Vaccine Research Center, part of NIH’s National Institute of Allergy and Infectious Diseases—will co-design and test mRNA vaccines against coronaviruses with the goal of developing vaccines that confer a more durable immune response.
Lead Product(s): mRNA-Based COVID-19 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Vaccine
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 29, 2022
Details:
Serum Institute of India has engaged GreenLight to design three messenger RNA products, including a vaccine for shingles. Serum Institute of India also has an option to expand the relationship further for two additional vaccine or therapeutic targets.
Lead Product(s): mRNA-based Therapy
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Vaccine
Partner/Sponsor/Collaborator: Serum Institute of India
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 14, 2022
Details:
This round of financing is aimed at establishing a scaled process under cGMP, capable of supporting clinical development and enabling the production of billions of doses of COVID-19 vaccine using GreenLight's proprietary bioprocessing technology.
Lead Product(s): mRNA vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Flu Lab
Deal Size: $17.0 million Upfront Cash: Undisclosed
Deal Type: Financing May 12, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
